393.99

0.58% 1.75

Alnylam Pharmaceuticals Inc (ALNY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALNY? Forum Prognose

Schlusskurs vom Vortag:

$392.24

Offen:

$388.68

24-Stunden-Volumen:

579.12K

Relative Volume:

0.59

Marktkapitalisierung:

$51.35B

Einnahmen:

$2.35B

Nettoeinkommen (Verlust:

$-269.70M

KGV:

-188.51

EPS:

-2.09

Netto-Cashflow:

$-75.39M

1W Leistung:

+19.99%

1M Leistung:

+22.50%

6M Leistung:

+45.42%

1J Leistung:

+46.88%

1-Tages-Spanne:

$382.19

$399.00

1-Wochen-Bereich:

$323.74

$402.43

52-Wochen-Spanne:

$205.87

$402.43

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Firmenname

Alnylam Pharmaceuticals Inc

Sektor

Healthcare (1168)

Branche

Biotechnology (646)

Telefon

(617) 551-8200

Adresse

675 WEST KENDALL STREET, CAMBRIDGE, MA

Mitarbeiter

2,230

Twitter

@alnylam

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

ALNY's Discussions on Twitter

Vergleichen Sie ALNY mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALNY Alnylam Pharmaceuticals Inc	393.82	44.31B	2.35B	-269.70M	-75.39M	-2.09
VRTX Vertex Pharmaceuticals Inc	456.51	120.48B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	549.27	59.88B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	674.86	36.65B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	296.12	32.46B	3.81B	-644.79M	-669.77M	-6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-30	Fortgesetzt	Raymond James	Outperform
2025-07-21	Eingeleitet	Truist	Buy
2025-03-31	Eingeleitet	Redburn Atlantic	Buy
2025-03-24	Hochstufung	JP Morgan	Neutral → Overweight
2024-11-12	Herabstufung	Wolfe Research	Peer Perform → Underperform
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-08-16	Hochstufung	Goldman	Neutral → Buy
2024-02-16	Herabstufung	Goldman	Buy → Neutral
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2023-12-08	Eingeleitet	Wells Fargo	Equal Weight
2023-10-11	Herabstufung	Oppenheimer	Outperform → Perform
2023-09-29	Eingeleitet	Raymond James	Outperform
2023-05-05	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-04-26	Eingeleitet	SMBC Nikko	Neutral
2023-03-21	Eingeleitet	Bernstein	Outperform
2023-01-18	Eingeleitet	Canaccord Genuity	Buy
2022-09-09	Fortgesetzt	Morgan Stanley	Equal-Weight
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-06-27	Herabstufung	Guggenheim	Buy → Neutral
2022-06-07	Eingeleitet	William Blair	Outperform
2022-04-25	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-03-01	Eingeleitet	Citigroup	Buy
2022-02-03	Hochstufung	Guggenheim	Neutral → Buy
2022-01-03	Hochstufung	Piper Sandler	Neutral → Overweight
2021-11-22	Hochstufung	Goldman	Neutral → Buy
2021-11-22	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2021-11-01	Hochstufung	Oppenheimer	Perform → Outperform
2021-10-04	Hochstufung	UBS	Neutral → Buy
2021-08-04	Herabstufung	Piper Sandler	Overweight → Neutral
2021-02-22	Herabstufung	Guggenheim	Buy → Neutral
2021-02-12	Herabstufung	Citigroup	Buy → Neutral
2021-02-12	Bestätigt	H.C. Wainwright	Buy
2021-01-25	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2020-09-30	Fortgesetzt	Berenberg	Hold
2020-09-08	Eingeleitet	Citigroup	Buy
2020-08-11	Herabstufung	Oppenheimer	Outperform → Perform
2020-05-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2020-05-07	Herabstufung	JP Morgan	Overweight → Neutral
2020-04-24	Fortgesetzt	Evercore ISI	Outperform
2020-03-19	Eingeleitet	Berenberg	Buy
2019-12-19	Bestätigt	Chardan Capital Markets	Buy
2019-11-20	Eingeleitet	Oppenheimer	Outperform
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-05-23	Fortgesetzt	Goldman	Neutral
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2019-03-06	Hochstufung	Evercore ISI	In-line → Outperform
2019-03-05	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2019-01-23	Eingeleitet	UBS	Neutral
2018-10-01	Eingeleitet	Cantor Fitzgerald	Overweight
2018-08-13	Bestätigt	Stifel	Buy
2018-08-07	Hochstufung	Stifel	Hold → Buy
2018-05-04	Bestätigt	Stifel	Hold
2018-03-28	Eingeleitet	Evercore ISI	In-line

Alle ansehen

Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten

08:33 AM

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2025 Earnings Call Transcript - Insider Monkey

08:33 AM

08:31 AM

What catalysts could drive Alnylam Pharmaceuticals Inc. stock higher in 2025Value Investing Recommendation For Consistent Profits - jammulinksnews.com

08:31 AM

05:10 AM

Alnylam Pharmaceuticals Lifts Revenue Outlook After Earnings Beat - Finimize

05:10 AM

02:36 AM

Alnylam Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Widens 292% - AInvest

02:36 AM

02:16 AM

Amvuttra's stellar performance pushes Alnylam's guidance, stock higher - FirstWord Pharma

Jul 31, 2025

Alnylam Pharmaceuticals Surges 15.43% On Strong Technical Breakout - AInvest

Jul 31, 2025

Alnylam: Q2 Earnings Snapshot - Greenwich Time

Jul 31, 2025

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches - insights.citeline.com

Jul 31, 2025

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast - inkl

Jul 31, 2025

Alnylam's Amvuttra: A Game-Changer in ATTR-CM and a Catalyst for Biotech Growth - AInvest

Jul 31, 2025

Alnylam: Amvuttra Is Just Getting Started (NASDAQ:ALNY) - Seeking Alpha

Jul 31, 2025

Alnylam reaches new highs on strong sales of closely watched rare disease drug - BioPharma Dive

Jul 31, 2025

Earnings call transcript: Alnylam’s Q2 2025 results boost stock by 18% - Investing.com Nigeria

Jul 31, 2025

Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates - Investing.com

Jul 31, 2025

Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates By Investing.com - Investing.com Canada

Jul 31, 2025

Alnylam Pharmaceuticals Surpasses Wall Street Expectations in Q2News and Statistics - IndexBox

Jul 31, 2025

Alnylam jumps on full year revenue guidance raise (ALNY) - Seeking Alpha

Jul 31, 2025

Alnylam Q2 2025 slides: ATTR-CM launch drives 64% revenue growth, guidance raised - Investing.com Canada

Jul 31, 2025

Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Jul 31, 2025

Alnylam Pharmaceuticals Skyrockets 12.3%—What’s Fueling This Biotech Surge? - AInvest

Jul 31, 2025

Alnylam Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Jul 31, 2025

Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance

Jul 31, 2025

Why is Alnylam Pharmaceuticals Inc. stock attracting strong analyst attentionStock Market Guidance With High Returns - jammulinksnews.com

Jul 31, 2025

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results - TradingView

Jul 31, 2025

ALNYLAM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

Jul 31, 2025

Alnylam Q2 2025 rev. $672 mln, up 64% YoY, raises TTR guidance to $2.175 bln-$2.275 bln. - AInvest

Jul 31, 2025

Amvuttra's first full-quarter sales for ATTR-CM are in. And they're a boon for Alnylam - Endpoints News

Jul 31, 2025

RNAi biotech founded by former Alnylam CEO expands Cambridge footprint - The Business Journals

Jul 31, 2025

Alnylam Outpaces The Market With RNAi Growth Story - Finimize

Jul 31, 2025

Jul 30, 2025

From inception to launch: City Therapeutics finds space in the heart of innovation - JLL

Jul 30, 2025

Alnylam Pharmaceuticals stock hits all-time high at 335.0 USD By Investing.com - Investing.com South Africa

Jul 30, 2025

Bernstein raises Alnylam Pharmaceuticals stock price target on Amvuttra outlook - Investing.com Canada

Jul 30, 2025

Jul 29, 2025

Raymond James assumes coverage on Alnylam stock with Outperform rating - Investing.com

Jul 29, 2025

Published on: 2025-07-29 22:59:43 - metal.it

Jul 29, 2025

Jul 28, 2025

What are the technical indicators suggesting about Alnylam Pharmaceuticals Inc.Market Forecast Review For 2025 - jammulinksnews.com

Jul 28, 2025

Published on: 2025-07-29 02:19:48 - metal.it

Jul 28, 2025

Published on: 2025-07-29 01:41:26 - metal.it

Jul 28, 2025

When is Alnylam Pharmaceuticals Inc. stock expected to show significant growthOutstanding capital returns - jammulinksnews.com

Jul 28, 2025

What makes Alnylam Pharmaceuticals Inc. stock price move sharplyDiscover high-growth stocks for your portfolio - jammulinksnews.com

Jul 28, 2025

What are Alnylam Pharmaceuticals Inc. company’s key revenue driversStay informed with daily expert analysis - jammulinksnews.com

Jul 28, 2025

Risk adjusted return profile for Alnylam Pharmaceuticals Inc. analyzedChart Breakout Buy Signal Detection Confirmed - metal.it

Jul 28, 2025

Jul 27, 2025

How does Alnylam Pharmaceuticals Inc. compare to its industry peersDiscover undervalued stocks before they soar - jammulinksnews.com

Jul 27, 2025

What are the latest earnings results for Alnylam Pharmaceuticals Inc.Navigate market volatility with smart strategies - jammulinksnews.com

Jul 27, 2025

What are analysts’ price targets for Alnylam Pharmaceuticals Inc. in the next 12 monthsUncover the best stocks for explosive growth - jammulinksnews.com

Jul 27, 2025

Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attentionFree Join Group - metal.it

Jul 27, 2025

How does Alnylam Pharmaceuticals Inc. generate profit in a changing economyInvest smarter with data-backed trading alerts - jammulinksnews.com

Jul 27, 2025

Jul 26, 2025